Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
about
Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?One for All? Hitting Multiple Alzheimer's Disease Targets with One DrugLong-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamusAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityPotentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitusMolecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisalThe role of gut endocrine cells in control of metabolism and appetiteType 2 diabetes and cognitive impairment: contributions from neuroimagingNew drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseasesNeural control of energy balance: translating circuits to therapiesBrain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogsDrug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideAlzheimer's disease and type 2 diabetes via chronic inflammatory mechanismsGlucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malariaThe glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodentsGLP-1 improves neuropathology after murine cold lesion brain traumaNeuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.Optimal therapy of type 2 diabetes: a controversial challengeThe nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemLong-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational studyIncretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryGLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-contChronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models.Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetesElucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells.Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury.Brain GLP-1 and insulin sensitivity.Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Sex and estrogens alter the action of glucagon-like peptide-1 on reward.The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepirideIn Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways.
P2860
Q26744254-5218596D-0B0A-4071-9147-2B60180C7087Q26747572-D326B194-25A0-4898-B2B0-09B1A70728DAQ26749191-77BBC83C-7372-4800-A288-25ECFB30B871Q26750746-0736BA8D-0AB6-4CB1-B9B7-D061036353C8Q26765609-0C33808E-EF2E-4998-8D0F-75078BE25C7EQ26774021-2F19BD14-CB6C-4A32-B6B7-4F10AE19D48EQ26783344-D7B13FCF-A9E9-4308-9458-F070EDCDF92EQ26824311-882A20EA-7B8F-4E7A-9821-C843A44B334AQ26825253-2A940549-E643-4949-A60D-0E4C981E8F26Q26866194-6B57C4CC-E54F-48F4-9877-89E095F0224BQ27005992-B0B55027-5ED2-477C-94C8-6BBF2895AB95Q27012801-5651172B-A5CE-461F-97BD-A86BA8B15F06Q27024122-7A46FB57-4CAB-4A4D-A77C-13B1FC2391EBQ28081671-11D3CCC4-5740-4015-B719-8490F149ECD9Q28086892-D330089E-159B-4A81-8F1D-6A5D7906826DQ28597322-CB370982-3EAA-4F0D-9517-63F874809596Q28598004-711CB372-CECF-458B-8318-C6B81235E88BQ28651569-38D72D5C-C26D-47DA-A8E4-A8897B0E0D97Q30412673-EC2DBA3B-CF39-4307-A0C7-ACBED974C7DEQ33577712-DE3DA084-1699-4B64-BBB5-9FD4B3DCC84FQ33600053-427E1CB2-7FD7-41E8-9C03-5FA2AD46086DQ33626001-1233BBCB-2338-4E33-856A-86F10345D16EQ33959406-77F6E4B9-9508-4CBA-B03A-3AEC2B1E87E5Q34062829-622B03F7-8EDE-4DC7-98F4-8E13F42E1078Q34202922-893E9853-516D-4298-AB87-F1393E2C08DDQ34362412-77205609-727A-4C47-A898-D6BDAEDE377EQ34511743-672EBE8F-B166-406A-B8E4-FF93713B3B06Q34639384-F4CAC7A2-838C-4133-800D-89226602F4F0Q34745109-C75A0EC2-615C-4298-9317-C5D96B95753AQ35106896-38C72EB7-650B-4A6D-940E-631C4EFE4F84Q35213829-D81FB8B1-263B-412F-A427-44094F1A11D1Q35306023-A2AB773E-A061-44CF-ABE2-CA0A680D8BAEQ35589875-8A22E483-7AAD-40F2-9666-439FF7FB1F8FQ35991683-131A09FA-D0CE-496F-90AE-B2F754CAD0C6Q36078803-1F3BD902-81CE-43E8-9754-2B138D2946D3Q36406821-020BC68F-44CB-4B77-A148-E494065D4EF8Q36469127-8FC860C9-20C1-4F20-8C25-FD3D612E3079Q36720655-79134C01-9B6E-4024-8507-E17B26807EBAQ36928283-66022944-03FD-4FA4-A924-EB071E375DA0Q36950218-3B6CA5E0-8AAA-4759-BC33-838C3B9078A6
P2860
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Drugs developed to treat diabe ...... rier and enhance neurogenesis.
@ast
Drugs developed to treat diabe ...... rier and enhance neurogenesis.
@en
type
label
Drugs developed to treat diabe ...... rier and enhance neurogenesis.
@ast
Drugs developed to treat diabe ...... rier and enhance neurogenesis.
@en
prefLabel
Drugs developed to treat diabe ...... rier and enhance neurogenesis.
@ast
Drugs developed to treat diabe ...... rier and enhance neurogenesis.
@en
P2860
P356
P1433
P1476
Drugs developed to treat diabe ...... rier and enhance neurogenesis.
@en
P2093
Christian Hölscher
Kerry Hunter
P2860
P2888
P356
10.1186/1471-2202-13-33
P577
2012-03-23T00:00:00Z
P5875
P6179
1045294653